Precision BioSciences, Inc. (DTIL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$4.79

P/E Ratio

93.74

Market Cap

$36.74M

Description

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Metrics

Overview

  • HQDurham, NC
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerDTIL
  • Price$4.79+2.13%

Trading Information

  • Market cap$36.74M
  • Float91.72%
  • Average Daily Volume (1m)200,447
  • Average Daily Volume (3m)128,369
  • EPS$0.08

Company

  • Revenue$75.10M
  • Rev growth (1yr)-95.61%
  • Net income-$16.43M
  • Gross margin-75.52%
  • EBITDA margin-3,518.06%
  • EBITDA-$20.26M
  • EV-$5.60M
  • EV/Revenue-0.07
  • P/E93.74
  • P/S0.46
  • P/B0.55
Documents